Search

Your search keyword '"Jessica M. Franklin"' showing total 168 results

Search Constraints

Start Over You searched for: Author "Jessica M. Franklin" Remove constraint Author: "Jessica M. Franklin" Database OpenAIRE Remove constraint Database: OpenAIRE
168 results on '"Jessica M. Franklin"'

Search Results

1. Development of a Medicare Claims–Based Model to Predict Persistent High‐Dose Opioid Use After Total Knee Replacement

2. Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting

Catalog

Books, media, physical & digital resources

3. 348 Development and validation of a claims-based algorithm for moderate-to-severe atopic dermatitis using U.S. real-world data

4. Linking the Paul Coverdell National Acute Stroke Program to commercial claims to establish a framework for real-world longitudinal stroke research

5. Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study

6. Prevalence of Avoidable and Bias‐Inflicting Methodological Pitfalls in Real‐World Studies of Medication Safety and Effectiveness

7. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies

8. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis

9. Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores

10. Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms

11. Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials

12. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?

13. Emulation Differences vs. Biases When Calibrating Real‐World Evidence Findings Against Randomized Controlled Trials

14. Evaluating the Utility of Coarsened Exact Matching for Pharmacoepidemiology Using Real and Simulated Claims Data

15. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises

16. Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride

17. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care

18. Glucose‐lowering medications and the risk of cancer: A methodological review of studies based on real‐world data

19. Evaluating the use of bootstrapping in cohort studies conducted with 1:1 propensity score matching—A plasmode simulation study

20. Days’ Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting — United States, 2014

21. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases

22. Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study

23. How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools

24. Real‐World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID‐19

25. Real-world evidence to support regulatory decision making: New or expanded medical product indications

26. Postoperative Inpatient Utilization of Opioid and Opioid-sparing Analgesics in the United States hospitals, 2007–2017

27. Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States

28. Abstract 13186: Prevalence, Predictors, and Outcomes of Both True- and Pseudo-resistant Hypertension in the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD)

29. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer

30. Propensity score prediction for electronic healthcare databases using Super Learner and High-dimensional Propensity Score Methods

31. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA

32. 133-LB: Cardiovascular Outcomes in Older Adults Initiating Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists: A Subgroup Analysis from the EMPRISE Study

33. Brief discussion on sampling variability in 1:1 propensity score matching without replacement

34. Predicting overdose among individuals prescribed opioids using routinely collected healthcare utilization data

35. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis

36. Changes in Outpatient Use of Antibiotics by Adults in the United States, 2006–2015

37. Predicting Adherence to Chronic Disease Medications in Patients with Long-term Initial Medication Fills Using Indicators of Clinical Events and Health Behaviors

38. Application and impact of run-in studies

39. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation

40. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records

41. Impact of State Laws Restricting Opioid Duration on Characteristics of New Opioid Prescriptions

42. Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts

43. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?

44. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development

45. Matching Weights to Simultaneously Compare Three Treatment Groups

46. Effects of expanding the look-back period to all available data in the assessment of covariates

47. Do patients trust the FDA?: a survey assessing how patients view the generic drug approval process

48. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications

49. Application and Impact of Run-In Studies for the Evaluation of Statin Efficacy and Safety

50. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care